Virax Biolabs to Present at 19th World Immune Regulation Meeting
Virax Biolabs (Nasdaq: VRAX) has announced its participation in the prestigious 19th World Immune Regulation Meeting (WIRM) taking place March 12-15, 2025, in Davos, Switzerland. The company's Chief Operating Officer, Dr. Nigel McCracken, will deliver a presentation titled 'Evaluation of T cell dysfunction in post acute infection syndromes' on March 12, 2025, at 20:00 in Foyer A1 of The Congress Center.
The biotechnology company, focused on viral disease diagnosis and immune response detection, will also showcase its immune profiling products at Booth 116. Management will be available to engage with research organizations and potential customers during the event.
WIRM 2025 is set to bring together approximately 600 scientists and clinicians worldwide, featuring scientific lectures, networking opportunities, and a poster exhibition in Davos.
Virax Biolabs (Nasdaq: VRAX) ha annunciato la sua partecipazione al prestigioso 19° Congresso Mondiale sulla Regolazione Immunitaria (WIRM), che si terrà dal 12 al 15 marzo 2025 a Davos, Svizzera. Il Chief Operating Officer dell'azienda, Dr. Nigel McCracken, presenterà un intervento intitolato 'Valutazione della disfunzione delle cellule T nei sindromi post-infezione acuta' il 12 marzo 2025 alle 20:00 nel Foyer A1 del Centro Congressi.
La società biotecnologica, focalizzata sulla diagnosi delle malattie virali e sulla rilevazione della risposta immunitaria, presenterà anche i suoi prodotti di profilazione immunitaria allo Stand 116. La direzione sarà disponibile per interagire con organizzazioni di ricerca e potenziali clienti durante l'evento.
Il WIRM 2025 riunirà circa 600 scienziati e clinici provenienti da tutto il mondo, offrendo conferenze scientifiche, opportunità di networking e una mostra di poster a Davos.
Virax Biolabs (Nasdaq: VRAX) ha anunciado su participación en el prestigioso 19° Encuentro Mundial sobre Regulación Inmunitaria (WIRM), que se llevará a cabo del 12 al 15 de marzo de 2025 en Davos, Suiza. El Director de Operaciones de la compañía, Dr. Nigel McCracken, presentará una conferencia titulada 'Evaluación de la disfunción de células T en síndromes post-infección aguda' el 12 de marzo de 2025 a las 20:00 en el Foyer A1 del Centro de Congresos.
La empresa biotecnológica, centrada en el diagnóstico de enfermedades virales y la detección de la respuesta inmune, también exhibirá sus productos de perfilado inmune en el Stand 116. La dirección estará disponible para interactuar con organizaciones de investigación y clientes potenciales durante el evento.
El WIRM 2025 reunirá a aproximadamente 600 científicos y clínicos de todo el mundo, presentando conferencias científicas, oportunidades de networking y una exposición de pósters en Davos.
Virax Biolabs (Nasdaq: VRAX)는 2025년 3월 12일부터 15일까지 스위스 다보스에서 열리는 권위 있는 제19회 세계 면역 조절 회의(WIRM)에 참여한다고 발표했습니다. 회사의 COO인 Dr. Nigel McCracken은 2025년 3월 12일 20:00에 컨벤션 센터 Foyer A1에서 '급성 감염 증후군 후 T 세포 기능 장애 평가'라는 제목의 발표를 할 예정입니다.
바이오테크 회사인 Virax Biolabs는 바이러스 질병 진단 및 면역 반응 검출에 중점을 두고 있으며, 부스 116에서 면역 프로파일링 제품도 선보일 예정입니다. 경영진은 행사 기간 동안 연구 기관 및 잠재 고객과 소통할 수 있도록 할 것입니다.
WIRM 2025는 전 세계에서 약 600명의 과학자 및 임상의가 모이는 행사로, 다보스에서 과학 강연, 네트워킹 기회 및 포스터 전시가 진행될 예정입니다.
Virax Biolabs (Nasdaq: VRAX) a annoncé sa participation au prestigieux 19ème Congrès Mondial sur la Régulation Immunitaire (WIRM), qui se déroulera du 12 au 15 mars 2025 à Davos, en Suisse. Le Directeur des opérations de l'entreprise, Dr. Nigel McCracken, présentera une conférence intitulée 'Évaluation de la dysfonction des cellules T dans les syndromes post-infection aiguë' le 12 mars 2025 à 20h00 dans le Foyer A1 du Centre des Congrès.
L'entreprise biotechnologique, axée sur le diagnostic des maladies virales et la détection de la réponse immunitaire, présentera également ses produits de profilage immunitaire au Stand 116. La direction sera disponible pour interagir avec des organisations de recherche et des clients potentiels durant l'événement.
Le WIRM 2025 rassemblera environ 600 scientifiques et cliniciens du monde entier, avec des conférences scientifiques, des opportunités de réseautage et une exposition de posters à Davos.
Virax Biolabs (Nasdaq: VRAX) hat seine Teilnahme an dem prestigeträchtigen 19. Weltmeeting zur Immunregulation (WIRM) angekündigt, das vom 12. bis 15. März 2025 in Davos, Schweiz, stattfinden wird. Der Chief Operating Officer des Unternehmens, Dr. Nigel McCracken, wird am 12. März 2025 um 20:00 Uhr im Foyer A1 des Kongresszentrums einen Vortrag mit dem Titel 'Bewertung der T-Zell-Dysfunktion bei postakuten Infektionssyndromen' halten.
Das Biotechnologieunternehmen, das sich auf die Diagnose von Viruskrankheiten und die Erkennung der Immunantwort spezialisiert hat, wird auch seine Produkte zur Immunprofilierung am Stand 116 präsentieren. Das Management wird während der Veranstaltung zur Verfügung stehen, um mit Forschungsorganisationen und potenziellen Kunden in Kontakt zu treten.
WIRM 2025 wird voraussichtlich etwa 600 Wissenschaftler und Kliniker aus der ganzen Welt zusammenbringen und wissenschaftliche Vorträge, Networking-Möglichkeiten und eine Poster-Ausstellung in Davos bieten.
- None.
- None.
Presentation Details:
Title: Evaluation of T cell dysfunction in post acute infection syndromes
Presenter: Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs
Date: Wednesday, March 12, 2025, at 20:00
Location: Foyer A1, The Congress Center, Davos,
Additionally, the Company will be showcasing its portfolio of immune profiling products for research use at Booth 116, and management will be available for discussions with research organizations and potential customers.
WIRM 2025 is an esteemed conference where approximately 600 scientists and clinicians from around the globe gather to discuss the latest advancements in immunology. This four-day event combines top-tier scientific lectures, informal networking, and a poster exhibition, all set against the stunning backdrop of
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-to-present-at-19th-world-immune-regulation-meeting-302392440.html
SOURCE Virax Biolabs
FAQ
When and where will Virax Biolabs (VRAX) present at WIRM 2025?
What will be the topic of Virax Biolabs' presentation at WIRM 2025?
Where can attendees find Virax Biolabs' product showcase at WIRM 2025?
How many participants are expected at WIRM 2025 where VRAX is presenting?
What products will Virax Biolabs (VRAX) showcase at WIRM 2025?
